NCT05920135View on ClinicalTrials.gov

First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 11, 2023

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2028

Conditions
EGFR Mutant Advanced Non-Small Cell Lung Cancer
Interventions
DRUG

BBT-207

BBT-207 given orally alone

Trial Locations (3)

13620

Seoul National University Bundang Hospital, Seongnam-si

03080

Seoul National University Hospital, Seoul

06351

Samsung Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Bridge Biotherapeutics, Inc.

INDUSTRY

NCT05920135 - First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI | Biotech Hunter | Biotech Hunter